Showing results (1-10 of 126) with videos related to

Sort By:
Pageof 13
Expert Opinion on Investigational Drugs|July 12, 2008
ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancerRuth Warren, Glenn Liu
Cancer Journal (Sudbury, Mass.)|October 18, 2016
Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer: A ReviewChristos E Kyriakopoulos, Glenn Liu
Current Opinion in Urology|February 21, 2013
Imaging of castration-resistant prostrate cancer: development of imaging response biomarkersCourtney Morisson, Robert Jeraj, Glenn Liu
Research Square|February 27, 2026
Progression-Free Survival versus Overall Survival in Patients with PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP versus PlaceboDouglas McNeel, Jens Eickhoff, Arianna Perez, et al.
Clinical Advances in Hematology & Oncology : H&O|March 11, 2009
Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesinsMichael R Harrison, Kyle D Holen, Glenn Liu
Nuclear Medicine Communications|September 18, 2015
Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancerUrban Simoncic, Scott Perlman, Glenn Liu, et al.
Oncology (Williston Park, N.Y.)|September 26, 2009
Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumorMichael R Harrison, Wei Huang, Glenn Liu, et al.
Cancer Investigation|December 7, 2007
Endothelin receptor antagonists in cancer therapyMihailo Lalich, Douglas G McNeel, George Wilding, et al.
Clinical Prostate Cancer|January 8, 2005
Newer therapies in advanced prostate cancerRobert B Hegeman, Glenn Liu, George Wilding, et al.
Clinical Genitourinary Cancer|June 16, 2026
Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus PlaceboDouglas G McNeel, Jens C Eickhoff, Arianna Perez, et al.
Pageof 13